(Total Views: 151)
Posted On: 03/07/2019 8:13:34 PM
Post# of 154721
Trial:
150 pts--350 mg
150 pts--350 vs 525mg
200 pts--525 vs 700mg
Final Numbers should be:
350mg 225
525mg 175
700mg 100
Poster
350mg 229
525mg 115
700mg 43
Feb 1st PR,
Jan 31st Investors Presentation.
Poster:
March 4th PR
150 pts--350 mg
150 pts--350 vs 525mg
200 pts--525 vs 700mg
Final Numbers should be:
350mg 225
525mg 175
700mg 100
Poster
350mg 229
525mg 115
700mg 43
Feb 1st PR,
Quote:
CytoDyn currently has 45 patients enrolled in monotherapy with 700 mg, 29 additional patients who have switched from lower doses to the 700 mg dose and over 40 patients currently in screening to initiate 700 mg dose arm of monotherapy trial.
Jan 31st Investors Presentation.
Quote:
No reported SAEs related to PRO 140 –(670 patients with zero drug related SAE )
Poster:
Quote:
The safety of PRO140 (leronlimab) has been tested in over 650 subjects
March 4th PR
Quote:
Leronlimab (PRO 140) has successfully completed seven Phase 1/2/3 clinical trials in over 700 people, including
(0)
(0)
